Document is current
Any future updates will be listed below
-
Authors
Boughaleb, Hasnae https://orcid.org/0000-0002-5783-5645
Linden, Jerome https://orcid.org/0000-0003-2685-5368
Soni, Arvind
Fabian, Nathalie
Lobysheva, Irina https://orcid.org/0000-0002-4290-3625
Montiel, Virginie https://orcid.org/0000-0002-5769-9954
Momeni, Mona https://orcid.org/0000-0003-1965-2335
Docquier, Marie-Agnès
Robert, Annie https://orcid.org/0000-0003-3720-7331
Van Overstraeten, Nancy https://orcid.org/0000-0001-5330-6706
Balligand, Jean-Luc https://orcid.org/0000-0002-0522-4156
-
Funding
Funding for this research was provided by:
Gouvernement Wallon
Vives
B2start
SRIW
- License Information
-
More Information
Article History
Received: 30 April 2024
Revised: 27 January 2025
Accepted: 24 February 2025
First Online: 9 April 2025
Declarations
:
: The study protocol was approved by the ethical committee (Comité d’Ethique Hospitalo-Facultaire, CUSL), chaired by Prof. J-M Maloteaux, on July 16, 2019 (Approval Number: 2019/16JUL/323) and was registered in ClinicalTrials.gov (ID: NCT03994900). Each patient signed an informed consent form before starting the study.
: All authors gave their consent for publication.
: The creation of Spinovit, a spin-off company of UCLouvain was supported by the Walloon Region, which awarded a First Spin-Off grant and contributed to the PICA proof-of-concept clinical trial. JLB and NVO were stakeholders of Spinovit during the course of the clinical trial.
